Maxime Verhoeven

155 Cost-effectiveness of treat-to-target strategies over 5 years Supplementary Figure 1 Cost effectiveness acceptability curve for the TCZ based initiation treatment strategy groups versus the MTX initiation strategy group over 5 years, using the healthcare perspective. TCZ+MTX= initiation of tocilizumab + methotrexate strategy group; TCZ= initiation of tocilizumab + placebo- methotrexate strategy group; MTX= initiation of methotrexate + placebo-tocilizumab strategy group. Example: Using a willingness to pay of €50,000, the probability that TCZ+MTX or TCZ is more cost-effective compared to MTX is 0 or 0%, respectively. Supplementary Figure 2 Cost effectiveness acceptability curve for the TCZ based initiation treatment strategy groups versus the MTX initiation strategy group over 5 years, using the societal perspective (friction cost approach). TCZ+MTX= initiation of tocilizumab + methotrexate strategy group; TCZ= initiation of tocilizumab + placebo- methotrexate strategy group; MTX= initiation of methotrexate + placebo-tocilizumab strategy group. Example: Using a willingness to pay of €50,000, the probability that TCZ+MTX or TCZ is more cost-effective compared to MTX is 0 or 2%, respectively. 7